Eileen

Virta patient since 2017

Virta can reverse type 2 diabetes quickly and sustainably

Virta patients are transforming their health

Eighty-three percent of clinical trial patients remained with Virta at one year.¹ 60% reversed type 2 diabetes. This is the new normal in diabetes care.

Medication reduction that lasts

Virta's approach reduces the need for prescription medications. At one year, clinical trial patients eliminated 63% of diabetes-specific medications. 94% of patients eliminated or reduce insulin usage.¹

Blood sugar control without drugs

Virta patients see sustained improvement in HbA1c, on average experiencing a 1.3 point drop at one year. Meanwhile, patients receiving Usual Care saw no improvement in HbA1c.¹

Weight-loss as a "side benefit"

Improved metabolic health is our primary focus, but our patients lose weight, too—one of the many "side benefits" of the Virta Treatment. At one year, clinical trial patients lost 30 lbs. on average, or 12% of total body weight.¹

Side benefits, not side effects

CVD Risk Factors
12% relative reduction in 10-year Atherosclerotic CVD risk score (at one year)³
Blood Pressure
Improvements while reducing antihypertensive
medication use³
Inflammation
39% reduction at one year of C-reactive protein, a marker of inflammation¹
Fatty Liver Disease
Significant reductions in suspected liver steatosis and fibrosis⁴

Patients are replacing drugs with the Virta treatment. Here's why.

Virta Health¹
Insulin⁴⁻⁶
GLP-1⁴
DPP-4⁴
SGLT-2⁴
A1c Reduction
-1.3
-1.8
-1.2
-0.7
-0.7
Weight Change
-30 lbs
+3.9
-4.4
0
-4.4
Rx Cost Per Month
-$160
$365
$720
$380
$400

Real-world results that last

Our fast results and high-touch, individualized approach combine to deliver behavioral change that patients stick with for the long-term

Retention at One Year

Virta³
90%
Diabetes Medication Adherence⁷
48%
Weight Loss Programs⁸
13%
2-6x
Higher retention than benchmarks
Patients stick with Virta at a much higher rate than most other medication or nutritional programs.
Other 2 year outcomes
55%
Diabetes Reversal
of patients had an HbA1c
19%
Diabetes Reversal
of patients met the definition for partial remission
67%
Medication Eliminations
of all diabetes-specific medications discontinued
Notation

Rx reduction for the long-term

Our patients continue to eliminate medications like insulin beyond year 1, with 55% of completing patients achieving diabetes reversal at two years.²

Virta is leading the way on diabetes reversal research

Our ongoing clinical trial, now in its fifth year, is demonstrating what is possible when patients have a treatment and care team that work for them.

See our research
Citations by the American Diabetes Association
Virta Health research is cited in the 2019 and 2020 ADA standards of medical care, which include low-carbohydrate nutrition as a first-line therapy for diabetes treatment.

What is Virta like? Our patients say it best.

Eliminating insulin. Walking a 5k. Losing 50 pounds. Our patients explain what is possible with Virta by their side.

See more stories
Citations and Footnotes
  1. Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9
  2. Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-year Non-randomized Clinical Trial. Frontiers in Endocrinology. 2019; 10:348. DOI: 10.3389/fendo.2019.00348
  3. Virta Health Registry for Remote Care of Chronic Conditions. Health and economic outcomes as of March 2019
  4. Cavaiola TS, Pettus JH. Management Of Type 2 Diabetes: Selecting Amongst Available Pharmacological Agents. [Updated 2017 Mar 31]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425702/. Numbers selected represent midpoint in range.
  5. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, Montales MT, Kuriakose K, Sasapu A, Beebe A, Patil N, Musham CK, Lohani GP and Mirza W (2017) Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front. Endocrinol. 8:6. doi: 10.3389/fendo.2017.00006. HbA1c estimate represents midpoint of range.
  6. Beverley Balkau, Philip D. Home, Maya Vincent, Michel Marre, Nick Freemantle. Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care Aug 2014, 37 (8) 2108-2113; DOI: 10.2337/dc13-3010
  7. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307. Published 2016 Jul 22. doi:10.2147/PPA.S106821
  8. Martin CK, Talamini L, Johnson A, Hymel AM, Khavjou O. Weight loss and retention in a commercial weight-loss program and the effect of corporate partnership. Int J Obes (Lond). 2010;34(4):742–750. doi:10.1038/ijo.2009.276